ClinicalTrials.Veeva

Menu

Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study

Duke University logo

Duke University

Status

Completed

Conditions

Chronic Kidney Disease
Hypertension

Treatments

Other: Control Diet
Other: DASH Diet

Study type

Interventional

Funder types

Other

Identifiers

NCT02059811
Pro00048112

Details and patient eligibility

About

More than two-thirds of US adults with chronic kidney disease (CKD) have uncontrolled hypertension. Both hypertension and CKD are major independent risk factors for cardiovascular disease, which is the leading cause of death in the US. Fortunately, lowering blood pressure to recommended treatment targets not only slows the progression of CKD, but also improves cardiovascular outcomes. Controlling hypertension in this patient population, however, can be quite challenging. A lifestyle modification that effectively reduces blood pressure in both pre-hypertensive and hypertensive adults is the Dietary Approaches to Stop Hypertension (DASH) diet.

The purpose of this pilot study is to (1) determine the extent to which the DASH diet lowers blood pressure in hypertensive adults with moderate chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] 30-59 ml/min/1.73m2) and (2) establish that the DASH diet can be safely consumed by this patient population.

Full description

During a 7-day run-in phase, participants will first consume a control diet similar in nutrient composition to the control diet of previous DASH studies. The control diet, which is a diet typical of most Americans, is reduced in servings of fruits, vegetables, low fat dairy products and relatively high in total and saturated fat. Immediately following the run-in phase, participants will receive the DASH diet during a 14-day intervention phase. Both diets will have the same sodium content and caloric intake will be adjusted for each participant to keep weight stable. All study meals and snacks will be provided.

Enrollment

42 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ≥18 years old
  • eGFR 30-59 ml/min/1.73m2
  • SBP ≥ 130 mmHg or DBP ≥ 80 mmHg
  • willing to eat one meal on-site 5 days/week

Exclusion criteria

  • baseline potassium >4.6 mEq/L while not taking potassium supplements (if potassium is ≥ 5.0 while taking potassium supplements, a potassium of 4.6 or less must be demonstrated off supplements
  • evidence of hyperkalemia (>5.1 mEq/L) within last 6 months
  • ≥ 0.5 mg/dl increase in serum creatinine in past 6 months
  • albumin-to-creatinine ratio > 200 mg/mmol
  • insulin requiring or poorly controlled diabetes mellitus
  • cardiovascular event within previous 6 months
  • change in anti-hypertensive medications in last 2 weeks, or anticipated medication change during study period
  • unwillingness to eat only study food for 21 day study period
  • unwillingness or inability to discontinue vitamin and mineral supplements or antacids containing potassium, magnesium or calcium
  • use of aldosterone antagonist
  • use of oral corticosteroids
  • alcohol intake >14 drinks/week
  • unstable doses of psychotropics or phenothiazine
  • weight reducing medications
  • use of medications for erectile dysfunction during study period
  • pregnant, breast feeding, or planning pregnancy during study period
  • chronic disease that may interfere with participation
  • history of organ transplant
  • any serious illness that would interfere with participation or make DASH diet unsafe
  • planning to leave the area during the study period
  • significant food allergies, preferences, or dietary requirements that would interfere with diet adherence
  • investigator discretion for safety or compliance reasons

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

42 participants in 1 patient group

DASH Diet
Experimental group
Description:
All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in "to-go" packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries.
Treatment:
Other: DASH Diet
Other: Control Diet

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems